Trial · NCT03189719
Results by group66
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 66
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) in Participants With Esophageal Squamous Cell Carcinoma (ESCC) Whose Tumors Are Programmed Cell Death-Ligand 1 (PD-L1) Biomarker-Positive (Combined Positive Score [CPS] ≥10) | Pembrolizumab + SOC | 13.9 | 95% Confidence Interval 11.1 to 17.7 | Months | |
| Overall Survival (OS) in Participants With Esophageal Squamous Cell Carcinoma (ESCC) Whose Tumors Are Programmed Cell Death-Ligand 1 (PD-L1) Biomarker-Positive (Combined Positive Score [CPS] ≥10) | Placebo + SOC | 8.8 | 95% Confidence Interval 7.8 to 10.5 | Months | |
| OS in Participants With ESCC | Pembrolizumab + SOC | 12.6 | 95% Confidence Interval 10.2 to 14.3 | Months | |
| OS in Participants With ESCC | Placebo + SOC | 9.8 | 95% Confidence Interval 8.6 to 11.1 | Months | |
| OS in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10) | Pembrolizumab + SOC | 13.5 | 95% Confidence Interval 11.1 to 15.6 | Months | |
| OS in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10) | Placebo + SOC | 9.4 | 95% Confidence Interval 8.0 to 10.7 | Months | |
| OS in All Participants | Pembrolizumab + SOC | 12.4 | 95% Confidence Interval 10.5 to 14.0 | Months | |
| OS in All Participants | Placebo + SOC | 9.8 | 95% Confidence Interval 8.8 to 10.8 | Months | |
| Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) As Assessed By Investigator in Participants With ESCC | Pembrolizumab + SOC | 6.3 | 95% Confidence Interval 6.2 to 6.9 | Months | |
| Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) As Assessed By Investigator in Participants With ESCC | Placebo + SOC | 5.8 | 95% Confidence Interval 5.0 to 6.1 | Months | |
| PFS Per RECIST 1.1 As Assessed By Investigator in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10) | Pembrolizumab + SOC | 7.5 | 95% Confidence Interval 6.2 to 8.2 | Months | |
| PFS Per RECIST 1.1 As Assessed By Investigator in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10) | Placebo + SOC | 5.5 | 95% Confidence Interval 4.3 to 6.0 | Months | |
| PFS Per RECIST 1.1 As Assessed By Investigator in All Participants | Pembrolizumab + SOC | 6.3 | 95% Confidence Interval 6.2 to 6.9 | Months | |
| PFS Per RECIST 1.1 As Assessed By Investigator in All Participants | Placebo + SOC | 5.8 | 95% Confidence Interval 5.0 to 6.0 | Months | |
| Objective Response Rate (ORR) Per RECIST 1.1 As Assessed By Investigator in All Participants | Pembrolizumab + SOC | 45.0 | 95% Confidence Interval 39.9 to 50.2 | Percentage of Participants | |
| Objective Response Rate (ORR) Per RECIST 1.1 As Assessed By Investigator in All Participants | Placebo + SOC | 29.3 | 95% Confidence Interval 24.7 to 34.1 | Percentage of Participants | |
| ORR Per RECIST 1.1 As Assessed By Investigator in Participants With ESCC Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10) | Pembrolizumab + SOC | 51.0 | 95% Confidence Interval 42.6 to 59.5 | Percentage of Participants | |
| ORR Per RECIST 1.1 As Assessed By Investigator in Participants With ESCC Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10) | Placebo + SOC | 28.0 | 95% Confidence Interval 20.8 to 36.1 | Percentage of Participants | |
| ORR Per RECIST 1.1 As Assessed By Investigator in Participants With ESCC | Pembrolizumab + SOC | 43.8 | 95% Confidence Interval 37.8 to 49.9 | Percentage of Participants | |
| ORR Per RECIST 1.1 As Assessed By Investigator in Participants With ESCC | Placebo + SOC | 31.0 | 95% Confidence Interval 25.6 to 36.9 | Percentage of Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03189719/results